Summit Therapeutics Share Discussion Threads

[luminoso] 28/3/2017 17:32

Would be good if nasdaq holds above 13 this evening.

[waterloo01] 28/3/2017 16:41

Hope we hear tomorrow that recruitment is complete and the 1st biopsy results are on track to report. Starts to get interesting building into the results, although I'm sure cautious heads will want to see the update following as it will (one hopes) finally demonstrate that utrophin upregulation does have an effect on the progress of the disease. That would be a very good moment and a long time coming.

[hugus maximus] 28/3/2017 15:50

Hi football - that's because on current dollar / pound rates, the NASDAQ opening price would be just a tiny smidge over £2 ... we've been unusually sailing a couple of hands above the NASDAQ for some time.

[football] 28/3/2017 15:28

Summit Therapeutics PLC (ADR)
NASDAQ: SMMT - Mar 28, 9:51 AM EDT
13.42USDPrice increase0.80 (6.34%)


but down here....


:(

[chrisatrdg] 27/3/2017 15:23

As reported by Proactive Investors today:

Summit rises as it presses on with extension of PhaseOut DMD trial

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) is to proceed with the planned extension phase of PhaseOut DMD, subject to regulatory approval.

PhaseOut DMD is a Phase 2 clinical trial evaluating the utrophin modulator ezutromid as a treatment for Duchenne muscular dystrophy (DMD).

The decision to press on with the trial follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data Monitoring Committee and its support of Summit's plans to extend the clinical trial.

Read Summit's DMD treatment granted US fast track status
Summit has now applied for regulatory approval to extend PhaseOut DMD from the UK Medicines and Healthcare products Regulatory Agency and Ethics Committee, and has submitted the necessary regulatory updates to the US Food and Drug Administration.

The submissions should pave the way for patients participating in PhaseOut DMD onto an open-label extension phase – where participants know what treatment they are getting and there is no need for one group of participants to take a placebo – at the end of the initial 48-week dosing period.

The extension phase will be used to gather long term safety and efficacy data.

"The proposed extension phase will allow us to gather important long-term safety and efficacy data of ezutromid in patients with DMD that we believe will comprise part of a data package necessary for future applications for regulatory approval of ezutromid," said Ralf Rosskamp, MD, chief medical officer of Summit.

"While the PhaseOut DMD trial continues with the aim of establishing proof of concept for ezutromid, we are pleased to see that the DMC supports the trial's extension based on their review of the safety and tolerability data to date, which includes data from patients dosed over longer periods of time than have previously been tested," he added.

Shares in Summit rose 3.7% on the news and have more than doubled over the last year.

[waterloo01] 27/3/2017 14:48

Not sure what to read into today's news, except that there are no safety issues (always good to get confirmed) and that patients want to remain on the treatment, which is good and might suggest they are seeing some benefit, but not surprising given the limited options. All adds to the data package and possible early approval!

[algernon2] 27/3/2017 13:28

Good news today for 2 of my favourite shares both Summit and Oxford Biomedica.
I know there are a few of us here invested in both so a good day so far and I'm now off into town for a coffee to celebrate.Well done guys.

[hugus maximus] 27/3/2017 12:29

Am I the only one reading between the lines and this is a game changing RNS? Isn't this anticipation of a couple of things:
1. The possibility of insuring belt and braces P2 Phase Out trial going straight to Open Label market ultimately speeding up market access?
2. Trump fulfilling a promise to change regulations to get the FDA to speed these sorts of drugs to market and access straight into Open Label pushing the possibility of no P3 along?

[chrisatrdg] 27/3/2017 12:22

Looks like good news ref further safety clearance for current DMD Trials plus results sooner than I had expected:

Results:



SUMMIT TO EXTEND ONGOING PhaseOut DMD CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD:



Edit: Good number of Buys so far after RNS (Maybe there is more to this RNS as suggested below).

[football] 27/3/2017 12:15

We have to wait for the US to open before we know what we should be doing this side of the water it seems nowadays

[someuwin] 27/3/2017 12:11

No reaction to today's news.

[chrisatrdg] 23/3/2017 21:14

Just out on twitter

We're hiring! View open positions & find out more about joining our team advancing txs in #Duchenne & #Cdiff



Shows Summit on the move again reflects Glyn's earlier positive presentation.

[solomon] 23/3/2017 08:40

I think we ticked it up, vatnabrekk :-)

[waterloo01] 23/3/2017 08:29

Good to hear they have term sheets on the table re RDZ and whichever route they go, confirmed it will be non dilutive.

[football] 22/3/2017 23:36

Summit Therapeutics plc (SMMT) Charges Ahead 10.41%, Just After Opening Bell on March 22 to Bolster Health Care Stocks

[vatnabrekk] 22/3/2017 23:06

Hope it doesn't go too high until I get my top-up in the morning!

[chrisatrdg] 22/3/2017 18:44

This evening sounded positive to me & we may get some news on C-Diff this summer if they can agree a non partnership deal with Government type funding.

Edit: Based on NASDAQ close some people must also have thought there were some upbeat comments today - close $12.95 at 1.25 $ to £ = £2.07.
In addition high level of transactions - looking good maybe some upturn on AIM Thursday.

[hugus maximus] 22/3/2017 14:19

Tree shaking?

[solomon] 22/3/2017 14:06

High volume in US. Reached the average daily trading volume (3 month average I reckon)in the first half hour.

[football] 22/3/2017 13:43

Well not at $13.6 in the US now

[hugus maximus] 22/3/2017 13:39

We're suffering from what seems to be a general market wobble both here and in the USA re: Trump.

[football] 21/3/2017 11:16

Quick question of topic anyone here know or have anything to do with MELAS ie. a new research/testing that's happening as the Internet is pretty threadbare of anything to do with it


tia

[chrisatrdg] 20/3/2017 22:03

Thanks football for your post.

I found recording of Glyn very interesting & a better understanding of why we are where we are with C-Diff.

Good introduction for new investors.

Edit: Registration for Wednesday set up per link below:

[football] 20/3/2017 20:38

Boardroom Talk: Summit Therapeutics' long road to drug approval

Summit Therapeutics(SUMM) is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.










anyone subscrbe here?